Screening for kidney disease in people with diabetes

Over time, hyperglycaemia causes damage to the kidneys, causing albumin excretion into urine (albuminuria). Early stages of kidney disease are asymptomatic so people with diabetes should have their kidney function screened at least once per year.

Screening tests include:

- albumin/creatinine ratio in a spot urine sample
- eGFR using serum creatinine

| eGFR categories | | Persistent albuminuria categories | | | |
|-----------------|--------------------------------------|-----------------------------------|------------------------|-----------------------------|--------------------------|
| | | | Normal (A1) | Microalbuminuria (A2) | Macroalbuminuria (A3) |
| | | eGFR (ml/min/ 1.73 m²) | <30 mg/g <3 mg/mmol | 30-300 mg/g 3-30 mg/mmol | >300 mg/g >30 mg/mmol |
| G1 | Normal or high | ≥90 | | | |
| G2 | Mildly decreased | 60-89 | | | |
| G3a | Mildly to moderately decreased | 45-59 | | | |
| G3b | Moderately decreased | 30-44 | | | |
| G4 | Severely decreased | 15-29 | | | |
| G5 | Kidney failure | <15 | | | |

Adapted from Murton M et al. Advances in Therapy. 2021;38(1):180-200 with permission as per Creative Commons license CC BY-NC 4.0.

Two occasions of eGFR < 60 ml/min/1.73 m² and/or micro- or macroalbuminuria indicate diagnosis of DKD

- Very high risk of disease progression
- High risk of disease progression
- Moderate risk of disease progression
- Low risk of disease progression (if no other markers of DKD)

People with diabetes may need **medication dosage adjustment** if their kidney function declines.



Metformin treatment should be stopped if eGFR is <30 ml/min/1.73 m²



No dose adjustment is required for gliclazide or glipizide. Glimepiride should be started conservatively at 1 mg daily in people with CKD stages 3, 4 and 5 (without dialysis).



No dose adjustments are required for insulin.